资本风云丨从亏损到盈利213亿 ,金斯瑞“高光” 难持续

子弹财经
29 Mar

近日,多家CXO(医药研发生产外包)企业陆续发布2024年业绩公告,业绩情况持续分化。国内CXO领域的龙头企业药明康德,在2024年交出了上市以来首次业绩下滑的成绩单。其全年营收为392亿元,同比下滑2.7%;归母净利润达94.5亿元,同比下降1.63%。凯莱英也是如此,2024年,公司预计实现营收58-60亿元,同比下滑23%—25%,归母净利润预计8.5亿—10.5亿元,同比下滑54%—63%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10